CompletedPhase 2

Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation

United States131 participantsStarted 2011-10

Plain-language summary

The purpose of this study is to determine if additional ablation during the first procedure as the result of the ability to medically induce quiet atrial arrhythmias will improve clinical outcome in patients with atrial fibrillation thus decreasing the need for additional ablation procedures.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients \>18 and \<75 who are able to give informed consent undergoing atrial fibrillation ablation procedure.
✓. Paroxysmal Atrial fibrillation lasting = 7 days which is self-terminating. It is considered recurrent if two or more episodes occur.
✓. Failure or unwilling to take class I or III anti-arrhythmic drugs

Exclusion criteria

✕. History of asthma
✕. Patients with severe coronary artery disease, stable/unstable angina, or ongoing myocardial ischemia
✕. Previous cardiac surgery ( excluding CABG and mitral valve surgery)
✕. Symptomatic congestive heart failure including but not limited to NYHA III/IV and/or documented ejection fraction \<40% measured by acceptable cardiac testing,
✕. Left atrial diameter \>55mm
✕. Moderate to severe mitral or aortic valve disease
✕. Myocardial infarction within three months of enrollment
✕. Congenital heart disease where it increases the risk of an ablative procedure

What they're measuring

Freedom From Any Atrial Arrhythmias

Timeframe: 2- 14 months after Ablation procedure

Trial details

NCT IDNCT03032965

SponsorUniversity of Michigan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-07

Results submitted2017-09-28

View on ClinicalTrials.gov More Atrial Fibrillation trials